The FY2023 (Dec) proxy of Aclaris Therapeutics names 24 peer companies for pay. Among Aclaris Therapeutics and these peers, CEO pay was 5th highest of 10 and total shareholder return was 8th highest of 10.
5th highest of 10in Aclaris Therapeutics and its pay peers, FY2023 (Dec) by CEO pay:
$3.5M$9.7M
8th highest of 10in Aclaris Therapeutics and its pay peers, FY2023 (Dec) by total shareholder return:
$22$1,778
Pay peer group, FY2023 (Dec) proxy
| Kymera Therapeutics | ||
| Syndax Pharmaceuticals | ||
| Celldex Therapeutics | ||
| Anaptysbio | ||
| Nurix Therapeutics | ||
| Scholar Rock Holding | ||
| Aldeyra Therapeutics | ||
| Replimune Group | ||
| Stoke Therapeutics | ||
| AlloVir, Inc. | Not disclosed | Not disclosed |
| BioXcel Therapeutics, Inc. | Not disclosed | Not disclosed |
| C4 Therapeutics, Inc. | Not disclosed | Not disclosed |
| Chinook Therapeutics, Inc. | Not disclosed | Not disclosed |
| Day One Biopharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Design Therapeutics, Inc. | Not disclosed | Not disclosed |
| Evelo Biosciences, Inc. | Not disclosed | Not disclosed |
| IVERIC bio, Inc. | Not disclosed | Not disclosed |
| Inhibrx, Inc. | Not disclosed | Not disclosed |
| RAPT Therapeutics, Inc. | Not disclosed | Not disclosed |
| Selecta Biosciences, Inc. | Not disclosed | Not disclosed |
| Seres Therapeutics, Inc. | Not disclosed | Not disclosed |
| Vaxcyte | Not disclosed | Not disclosed |
| Ventyx Biosciences, Inc. | Not disclosed | Not disclosed |
| iTeos Therapeutics, Inc. | Not disclosed | Not disclosed |
24 companies
Changes by year
No proxy on file names a change to the peer group.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.